Enfusion, Inc. (NYSE:ENFN) Given Consensus Recommendation of “Reduce” by Brokerages

Enfusion, Inc. (NYSE:ENFN) has been given an average recommendation of “Reduce” by the six brokerages that are presently covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $9.33.

Several equities analysts have commented on the company. Morgan Stanley started coverage on Enfusion in a research report on Friday, May 10th. They set an “overweight” rating and a $11.00 price objective for the company. Bank of America lifted their price target on shares of Enfusion from $8.00 to $9.00 and gave the company an “underperform” rating in a research report on Wednesday, March 13th.

Enfusion Trading Up 0.3 %

Shares of ENFN opened at $8.43 on Wednesday. Enfusion has a 1-year low of $7.52 and a 1-year high of $11.56. The firm has a market capitalization of $1.08 billion, a price-to-earnings ratio of 280.83, a PEG ratio of 1.98 and a beta of 0.92. The firm’s 50-day moving average price is $9.04 and its 200-day moving average price is $9.03.

Enfusion (NYSE:ENFN) last posted its earnings results on Thursday, May 9th. The company reported ($0.01) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.05). The firm had revenue of $48.05 million for the quarter, compared to analysts’ expectations of $47.67 million. Enfusion had a return on equity of 6.60% and a net margin of 1.40%. During the same quarter last year, the company posted $0.04 EPS. On average, research analysts forecast that Enfusion will post 0.09 EPS for the current fiscal year.

Insider Transactions at Enfusion

In other news, insider Bronwen Bastone sold 18,241 shares of the company’s stock in a transaction that occurred on Thursday, June 20th. The shares were sold at an average price of $8.11, for a total value of $147,934.51. Following the transaction, the insider now owns 198,913 shares in the company, valued at $1,613,184.43. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, insider Bronwen Bastone sold 18,241 shares of the business’s stock in a transaction that occurred on Thursday, June 20th. The shares were sold at an average price of $8.11, for a total value of $147,934.51. Following the completion of the transaction, the insider now directly owns 198,913 shares in the company, valued at approximately $1,613,184.43. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Deirdre Somers sold 4,629 shares of the stock in a transaction on Friday, June 14th. The shares were sold at an average price of $8.40, for a total value of $38,883.60. Following the sale, the director now owns 43,312 shares in the company, valued at $363,820.80. The disclosure for this sale can be found here. Insiders sold a total of 36,318 shares of company stock valued at $296,688 in the last quarter. 36.44% of the stock is owned by insiders.

Institutional Investors Weigh In On Enfusion

Several large investors have recently bought and sold shares of ENFN. Allspring Global Investments Holdings LLC purchased a new stake in shares of Enfusion during the 1st quarter valued at about $44,000. Tower Research Capital LLC TRC boosted its holdings in Enfusion by 680.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 9,894 shares of the company’s stock worth $96,000 after purchasing an additional 8,627 shares during the last quarter. Barclays PLC grew its position in Enfusion by 29.0% in the 3rd quarter. Barclays PLC now owns 10,809 shares of the company’s stock worth $96,000 after purchasing an additional 2,430 shares during the period. Price T Rowe Associates Inc. MD bought a new stake in Enfusion in the 1st quarter worth approximately $102,000. Finally, Quadrature Capital Ltd bought a new position in shares of Enfusion during the 1st quarter valued at $109,000. 81.05% of the stock is currently owned by institutional investors.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.